I-Sens, Inc. appears in FDA records as the applicant for K260689, the CVS Advanced PLUS Blood Glucose Monitoring System, cleared with a Substantially Equivalent decision on October 2, 2026. The submission was received March 3, 2026, and reviewed in the Clinical Chemistry panel under 21 CFR 862.1345, product code NBW, device class 2. The filing is recorded as a Special 510(k) that was not reviewed by a third party. The applicant address in the FDA record is Banpo-Daero 28 Gil, 43, Seocho-Gu, Seoul, Korea. [1][2][6]
The documented FDA submission
K260689 covers a single named device, the CVS Advanced PLUS Blood Glucose Monitoring System, classified as a system, test, blood glucose, over the counter. FDA lists the decision as SESE, meaning Substantially Equivalent, dated October 2, 2026, with a decision summary available. The record shows no combination product designation and no authorized predetermined change control plan. [1][2][8]
The supplied collection contains one linked 510(k) record, and that single record carries a SESE decision. The smaller record sample likewise contains one entry with a SESE decision. These counts describe the retrieved filings as of the snapshot date and are not measures of company sales, total portfolio or safety performance. [1]
Product scope described by the manufacturer
I-Sens publishes its own product categories: blood glucose monitoring systems, continuous glucose monitoring systems, IVD or point-of-care systems, and veterinary care systems. The company describes itself as a global in vitro diagnostics company that researches, develops and produces products using biosensor and electrochemical technologies. [3][4]
Named products in the manufacturer’s documentation include CareSens, described as a self-monitoring blood glucose system meeting ISO 15197:2013 accuracy, hematocrit and interference criteria, and CareSens Air, described as the first domestically produced continuous glucose monitoring system with CE certification. The company also states that its blood glucose monitoring devices have been used in over 110 countries. [4]
Applicant identity and corporate signals
The FDA record identifies I-Sens, Inc. as the applicant, with a Seoul address and country code KR. The manufacturer’s published site lists a Seoul address at i-SENS Building, 43, Banpo-daero 28-gil, Seocho-gu, and a business registration number. The FDA filing address is not treated here as a verified headquarters designation. [1][7]
Company-published material refers to a 26th anniversary and to planned exhibition of next-generation CGM products at EASD 2026, alongside an IR presentation page. These are the manufacturer’s own announcements; no independent verification of ownership structure, parent entities or commercial availability is present in the numbered sources. [5]
Regulatory context
FDA has published guidance on blood glucose monitoring test systems for prescription point-of-care use, and separately on premarket submission content for device software functions issued June 14, 2023. These documents describe FDA expectations generally and are not evidence about the performance of the K260689 device. [9]
The K260689 record lists the review panel as Clinical Chemistry and the regulation as 862.1345. The device is recorded as class 2. No predicate device, clinical performance data or labeling content beyond the indications statement is available in the numbered sources. [1][6][8]

